On March 24, the CDE official website recently revealed that Fosun Kite FKC889 and Mingju Bio’s JWCAR029 are planned to be included in breakthrough therapy varieties
.
It is reported that the proposed indication of FKC889 is relapsed/refractory mantle cell lymphoma, and the proposed indication of JWCAR029 is adult relapsed and refractory mantle cell lymphoma after second-line or above treatment
.